Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by Winslow Capital Management LLC

Winslow Capital Management LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 561,926 shares of the biopharmaceutical company’s stock after selling 212,592 shares during the period. Winslow Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $217,752,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of REGN. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $291,560,000. Loomis Sayles & Co. L P raised its position in shares of Regeneron Pharmaceuticals by 49.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,715,305 shares of the biopharmaceutical company’s stock valued at $629,672,000 after buying an additional 567,188 shares during the period. Wellington Management Group LLP raised its position in shares of Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock valued at $2,377,590,000 after buying an additional 446,850 shares during the period. Harding Loevner LP raised its position in shares of Regeneron Pharmaceuticals by 76.8% in the first quarter. Harding Loevner LP now owns 557,400 shares of the biopharmaceutical company’s stock valued at $215,998,000 after buying an additional 242,162 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Regeneron Pharmaceuticals by 36.8% in the first quarter. Bank of New York Mellon Corp now owns 881,867 shares of the biopharmaceutical company’s stock valued at $341,733,000 after buying an additional 237,157 shares during the period. 67.23% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded up 2.3293% during trading on Thursday, reaching $534.1792. 1,093,508 shares of the company were exchanged. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55. The firm’s 50 day moving average price is $456.19 and its 200 day moving average price is $393.90. The company has a market capitalization of $56.39 billion, a PE ratio of 64.6628 and a beta of 1.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.42. Regeneron Pharmaceuticals had a return on equity of 22.99% and a net margin of 19.34%. The company had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. During the same period last year, the business earned $2.57 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 9.8% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $12.66 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by Winslow Capital Management LLC” was published by sleekmoney and is owned by of sleekmoney. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://sleekmoney.com/regeneron-pharmaceuticals-inc-regn-shares-sold-by-winslow-capital-management-llc/1931495.html.

Several research analysts have recently issued reports on REGN shares. Vetr raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $475.44 target price on the stock in a research note on Wednesday, March 15th. BMO Capital Markets reissued a “hold” rating and set a $412.00 price objective (up previously from $408.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 28th. Leerink Swann reissued an “outperform” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, March 20th. Canaccord Genuity raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $375.00 to $484.00 in a research note on Friday, May 5th. Finally, Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price objective on the stock in a research note on Thursday, April 27th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $438.99.

In related news, Director Michael S. Brown sold 1,000 shares of the stock in a transaction on Wednesday, March 29th. The stock was sold at an average price of $400.00, for a total value of $400,000.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $400,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Sanofi bought 136,050 shares of the business’s stock in a transaction that occurred on Friday, June 2nd. The stock was purchased at an average price of $478.17 per share, for a total transaction of $65,055,028.50. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 49,821 shares of company stock worth $23,253,312. 10.40% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/regeneron-pharmaceuticals-inc-regn-shares-sold-by-winslow-capital-management-llc/1931495.html

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *